Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Lynx1 Capital Management LP 13F Holdings -- Portfolio & Top Positions (2026-03-31)

Lynx1 Capital Management LP (CIK 1910456) reported $632.7M across 23 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: STOK ($155.1M, 24.51%), GHRS ($151.3M, 23.92%), CGEM ($127.4M, 20.13%), AGIO ($88.3M, 13.96%), DNLI ($36.1M, 5.71%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1STOKSTOKE THERAPEUTICS INC$155.1M24.51%4.8MTrimmed
2GHRSGH RESEARCH PLC$151.3M23.92%10.8MAdded
3CGEMCULLINAN THERAPEUTICS INC$127.4M20.13%9.0MHold
4AGIOAGIOS PHARMACEUTICALS INC$88.3M13.96%2.6MAdded
5DNLIDENALI THERAPEUTICS INC$36.1M5.71%1.9MAdded
6CCCCC4 THERAPEUTICS INC$18.4M2.91%7.0MTrimmed
7KRROKORRO BIO INC$17.4M2.75%1.5MAdded
8TCRXTSCAN THERAPEUTICS INC$8.1M1.28%8.0MHold
9XNCRXENCOR INC$6.5M1.02%536,398Trimmed
10DTILPRECISION BIOSCIENCES INC$5.4M0.86%985,113Trimmed
11PASGPASSAGE BIO INC$4.9M0.77%623,704Hold
12NEUPNEUPHORIA THERAPEUTICS INC$3.6M0.56%875,328Added
13TRDAENTRADA THERAPEUTICS INC$2.7M0.42%211,689Added
14CGONCG ONCOLOGY INC$2.1M0.34%31,591Hold
15IMTXIMMATICS N.V$2.1M0.34%216,973Trimmed
16DSGNDESIGN THERAPEUTICS INC$1.3M0.20%119,516Added
17VYNEVYNE THERAPEUTICS INC$973,1480.15%1.6MNew
18HOWLWEREWOLF THERAPEUTICS INC$547,6730.09%657,786Added
19BOLTBOLT BIOTHERAPEUTICS INC$124,4320.02%30,800New
20IBIOIBIO INC$129,3440.02%68,076New
21PRQRPROQR THRAPEUTICS N V$110,9470.02%68,486Hold
22ABSIABSCI CORPORATION$63,7350.01%21,245New
23APLTAPPLIED THERAPEUTICS INC$00.00%0Exited
24ARWRARROWHEAD PHARMACEUTICALS IN$00.00%0Exited
25GBIOGENERATION BIO CO$00.00%0Exited

Source: SEC Form 13F filings · as of 2026-03-31